

PepTID^X peptid-x.com v1

- Advancing Peptide Innovation
- Shaping Tomorrow's Therapies



7th & 8th September 2026
Six Senses Crans-Montana
Switzerland

a forum brought to you by
 **PolyPeptide**

Celebrating Peptide Innovation Shaping Tomorrow's Therapies

PepTID^x 2026 gathers leading innovators in peptide science – from world-class academic researchers to senior biotech and pharma decision-makers – for two days of focused, high-level exchange on the therapeutic breakthroughs redefining metabolic health and next-generation peptide modalities.

Sponsored by PolyPeptide Group and chaired by Bernard Thorens, this forum provides rare access to the ideas, technologies, and scientific perspectives driving the field forward.

Bernard Thorens Chairman & Moderator
**Professor emeritus
of the University of Lausanne**



Bernard Thorens is Professor emeritus of the University of Lausanne. He was the first to structurally and functionally characterize the GLP-1 receptor and the human GIP receptor. His work further described how these two hormones control pancreatic beta-cells mass and function.

On a separate line of investigations, he described a network of glucose sensing cells, located at different anatomical sites – in particular, in the central nervous system – which control glucose homeostasis and feeding behavior. Using genomics and physiological studies he also identified previously unknown regulators of fat, liver, pancreatic beta-cells and neuron function involved in whole body metabolic regulations.

His work has been funded by Swiss and European grants, including Advanced Research Grants from the European Research Council. He coordinated two large EU Innovative Medicine Initiative grants. He served as vice-president of the EASD (2012-2015). He was an elected member of the Research Council of the Swiss National Science Foundation; he is a member and of the Swiss Academy of Medical Sciences. His work has been recognized by several national and international awards, including the 2002 Cloëtta Award, the 2009 Albert Renold Award from the EASD, the 2017 Claude Bernard Award from the EASD, The Roger Assan Prize from the SFD, the 2024 Manpei Suzuki International Prize for Diabetes Research, Tokyo.

GLP-1: the medicines, the biology, and the learnings

> 7th September 2026 | 9:00

Lotte Bjerre Knudsen

**Honorary Professor in Translational
Medicine at Aarhus University**

Lotte Bjerre Knudsen is an Honorary Professor in Translational Medicine at Aarhus University, Denmark. She holds a degree in biotechnology from the Technical University, and a Doctoral Degree in Scientific Medicine from the University of Copenhagen, both in Denmark.



Lotte Bjerre Knudsen is the former Chief Scientific Advisor for the SCO of Novo Nordisk, working there from 1989-2026. Lotte is a co-inventor of liraglutide and has led all biology research programs for liraglutide and semaglutide from diabetes to obesity, cardiovascular, liver, kidney and Alzheimer's Disease.

She has been part of representing Novo Nordisk in five FDA Advisory committees. Lotte holds a degree in biotechnology from the Technical University of Denmark, and a Doctoral Degree in Scientific Medicine from the University of Copenhagen, and she is an Adjunct Professor of Translational Medicine for Aarhus University.

Lotte has an H-index of 64, is an inventor on numerous patents, and most prominently a recipient of the Paul Langerhans Award, the Science Mani Bhaumik Breakthrough of the Year Award, the Lasker-DeBakey Clinical Research Award and the Breakthrough Prize of Life Sciences.

3

GLP-1 Analogues and their impact on patients – the doctor's perspective

> 7th September 2026 | 9:45



Katharina Timper

**Professor of Clinical Nutritional
Medicine, Univ.-Prof. Dr. med., TUM
(Technical University of Munich),
Helmholtz Munich and Else Kröner
Fresenius Center for Clinical
Nutritional Medicine**

Professor Katharina Timper studied human medicine at the University of Freiburg.

She is a board-certified specialist in endocrinology, diabetology and metabolism as well as in internal medicine. Before her appointment at TUM, she worked at the University Hospital of Basel in Switzerland, where she headed the university's interdisciplinary obesity center, clinical nutrition unit and outpatient clinic for eating disorders.

In May 2025, she was appointed Professor of Clinical Nutritional Medicine and Medical Director of Clinical Nutritional Medicine at the TUM University Hospital. Since October 2025, she has also headed the newly founded Institute for Translational Metabolism Research at Helmholtz Munich. She is also spokesperson for the Else Kröner Fresenius Center for Nutritional Medicine (EKfZ) at TUM, which investigates new approaches to the prevention and treatment of nutrition-related diseases.

Topic

Discovery of novel unimolecular tetra-agonist peptides for the treatment of obesity and related disorders

> 7th September 2026 | 11:00

Cristina M Rondinone
CEO and founder Pep2Tango
Therapeutics

4

Senior executive and biopharmaceutical leader with more than 25 years of experience driving the discovery and development of innovative medicines. Proven track record of leading multidisciplinary teams from target identification through late-stage clinical development, with contributions to multiple approved and late-stage therapies, including Rezdiffra, cotadutide, dorzagliatin, and bentracimab.



Co-Founder and CEO of Pep2Tango Therapeutics Inc., a biotechnology company developing next-generation unimolecular multi-agonist peptides for the treatment of obesity and related metabolic disorders.

Currently a member of the Health Council at TECNALIA and former member of the Board of Directors of Axcella (AXLA). Previously served as President of Cellarity Inc. and as Senior Vice President at AstraZeneca (MedImmune), where she led Research and Development for Cardiovascular, Metabolic, and Renal Diseases.

Prior to AstraZeneca, she held senior leadership roles at Hoffmann-La Roche and Abbott Laboratories, where she led multiple programs, including the discovery of Rezdiffra. Before joining industry, she was an Associate Professor (Docent) of Molecular Medicine at the University of Gothenburg, Sweden.

She earned a Ph.D. in Biochemistry from the University of Buenos Aires and completed postdoctoral training at the Laboratory of Cellular and Developmental Biology at the NIDDK, National Institutes of Health (NIH), USA. She has authored more than 80 scientific publications, holds 10 patents, and is an inducted member of the Royal Academy of Pharmacy and Biochemistry, Spain

From GLP-1 to Nutrient-Stimulated Polyagonists: from T2D to Obesity to Cardiorenalmetabolism and Beyond

Topic

> 7th September 2026 | 11:45



Robert Augustin Business Development and Licensing, Boehringer Ingelheim

Robert Augustin is a biochemist by training with 15 plus years of international experience in cardiometabolic research in academia and industry leading people, teams, projects, and collaborations.

Before joining the Business Development and Licensing organization at Boehringer Ingelheim in 2023, Robert worked in Cardiorenalmetabolic research, Translational Medicine, Project Management and Non-clinical Development at Boehringer Ingelheim and in the GLP-1 biology at Novo Nordisk.

As a drug discovery professional, he comes with a track record to deliver clinical stage assets – e.g. the GCGR/GLP-1R dual agonist survodutide, the NPY2R agonist BI 1820237, and the novel first-in class triple agonist BI 3034701, peptide hormone mimetics for the treatment of people with obesity and cardiorenalmetabolic diseases.

5

Nano- and microtechnologies for the oral delivery of peptides

Topic

> 7th September 2026 | 14:00

Patrick Couvreur Emeritus Professor at Paris-Saclay University

Emeritus Professor at Paris-Saclay University, Patrick COUVREUR is a member of the Academy of Sciences and chair of the Committee "Evaluation and Open Science" of this Academy. He held the "Liliane Bettencourt Technological Innovations" chair at the Collège de France.



His research focuses on the design and development of nanomedicines for oncology and neurological diseases treatments. He is the founder of three startups, one of which, Bioalliance, went public and developed a nanomedicine that reached the end of phase III clinical trials for the treatment of hepatocarcinoma.

Patrick COUVREUR has received numerous scientific distinctions in France (Prix Galien, Médaille de l'Innovation du CNRS, Grand Prix de Chimie Achille Le Bel...) and abroad (Host Madsen Medal, European Inventor Award, Acta Biomaterialia Gold Medal, CRS Founder Award...) ; he is an honorary doctorate from several foreign universities. In addition to the Academy of Sciences, he is also a member in France of the National Academy of Medicine, the Academy of Technologies, and was the 2020 President of the National Academy of Pharmacy.

Abroad, he is a member of the National Academy of Medicine (USA), the National Academy of Engineering (USA), the Royal Academy of Medicine (Belgium), the Real Academia Nacional de Farmacia (Spain), and the Academy of Pharmaceutical Sciences and Technology (Japan).

Metabolic space What's next ?

Round-table > Bernard Thorens: 7th September 2026 | 14:45 - 15:45

6

Dive into the evolving peptide landscape with insights from global leaders shaping next-generation therapeutics. Topics include GLP-1 innovations, the clinician's view on metabolic diseases.

Afternoon sessions explore emerging peptide classes, manufacturing trends, and the expanding metabolic space.

Topic

The Infinite Loop: ML for Discovery, Delivery, and Rapid Manufacturing of Potential Medicines

> 8th September 2026 | 8:00



Bradley L. Pentelute
Professor of Chemistry at MIT

Bradley L. Pentelute is a Professor of Chemistry at MIT pentelutelabmit.com.

He is also an Associate Member, Broad Institute of Harvard and MIT, an Extramural Member of the MIT Koch Cancer Institute, and Member, Center for Environmental Health Sciences MIT.

He received his undergraduate degree in Psychology and Chemistry from the University of Southern California, and his M.S and Ph.D. in Organic Chemistry from the University of Chicago with Prof. Steve Kent.

He was a postdoctoral fellow in the laboratory of Dr. R. John Collier at Harvard Medical School, Microbiology.

Reprogramming the genetic code to unlock the potential of recombinant strategy for peptide manufacturing

Topic

> 8th September 2026 | 8:45

Jason Chin

Founding Director of the Generative Biology Institute (GBI)

Jason is Founding Director of the Generative Biology Institute (GBI) at the Ellison Institute of Technology, Oxford, a Professor of Chemistry and Chemical Biology at the University of Oxford Department of Chemistry and a fellow of Magdalen College, Oxford.



7

He is also founder and CSO of Constructive Biology Ltd, which develops and applies his foundational advances in engineering biology and synthetic biology, and a Non-Executive Director at the Department of Science, Innovation and Technology. Prior to the launch of GBI, Jason was a Programme Leader at the Medical Research Council Laboratory of Molecular Biology (MRC-LMB), where he was also Founder and Head of the Centre for Chemical & Synthetic Biology (CCSB) and joint Head of the Division of Protein and Nucleic Acid Chemistry. He was also a Professor of Chemistry and Chemical Biology at the University of Cambridge Department of Chemistry, and a fellow of Trinity College, Cambridge.

Jason was awarded the Francis Crick Prize by the Royal Society in 2009 and the Royal Society of Chemistry's Corday Morgan Prize and the European Molecular Biology Organization's (EMBO) Gold Medal, in 2010. He is the inaugural recipient (2011) of the Louis-Jeantet Young Investigator Career Award and in 2019 he was awarded the Sackler International Prize in the Physical Sciences. Jason is in the European Patent Office Inventor Hall of Fame, a member of EMBO, and was awarded an honorary doctorate from ETH, Zurich in 2024. He is a Fellow of the Academy of Medical Sciences, and a Fellow of The Royal Society.

Advances in AI Enabled Peptide Design: Structural Trends and the Expanding Role of AlphaFold

> 8th September 2026 | 10:00



Bruno Correia

Associate Professor, Laboratory of Protein Design & Immunoengineering, EPFL (École Polytechnique Fédérale de Lausanne)

Throughout his PhD and postdoctoral studies he was trained in world-renowned laboratories and institutions in the United States of America (University of Washington and The Scripps Research Institute).

8 Very early in his scientific career he found out his fascination about protein structure and function. His PhD studies evolved in the direction of immunogen design and vaccine engineering which sparked his interest in the many needs and opportunities in vaccinology and translational research. His efforts resulted in an enlightening piece of work where for the first time, computationally designed immunogens elicited potent neutralizing antibodies. During his postdoctoral studies he joined a chemical biology laboratory at the Scripps Research Institute. In this stage he developed novel chemoproteomics methods for the identification of protein-small molecule interaction sites in complex proteomes.

In March 2015, he joined the École Polytechnique Fédérale de Lausanne (EPFL) – Switzerland as a tenure track assistant professor. The focus of his research group is to develop computational tools for protein design with particular emphasis in applying these strategies to immunoengineering (e.g. vaccine and cancer immunotherapy). The activities in his laboratory focus on computational design methods development and experimental characterization of the designed proteins.

Our laboratory has been awarded with 2 prestigious research grants from the European Research Council. Lastly, he has been awarded the prize for best teacher of Life sciences in 2019.

Diseconomies of Scale; how Automation, Process Intensification and Politics are changing Manufacture of Complex Molecules

> 8th September 2026 | 10:45

Andrew Rutter

Consultant Rutterdesign

Andrew Rutter leads a consultancy, rutterdesign, specialising in Advanced Manufacturing Technologies, the economics of supply chains, and Agile Factory Design for the manufacture of complex molecules. He is currently advising leading Pharmaceutical companies and Governments on how to accelerate their programmes to adopt technologies like Continuous Manufacture, Modularisation of Systems,



Automation, and the supporting Process Design Workflows – the means of utilising the technology.

Prior to setting up rutterdesign, he led the implementation of GSK's Continuous Manufacturing and advanced manufacturing programme, which culminated in the approval of 2 multistage Active Pharmaceutical processes. This programme explored applying modularised systems for small and large molecules, including vaccines and oligonucleotides. Before this he worked in Petrochemical Manufacture and for IBM. He also helped author ICH Guidance for Continuous Manufacture as a member of the ICH Q13 Expert Working Group.

Outside of consulting, he is a Visiting Professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences, and is actively researching methodologies for linking Chemistry, Engineering and Supply Chain decisions. Andrew is a Fellow of the Royal Academy of Engineers, as a Fellow he has advised the UK government on Systems Engineering approaches to solving complex problems, and participated in resilient manufacture discussions.

The promises of peptide science for medicine

Round-table > Bernard Thorens: 8th September 2026 | 11:30 - 12:30

Day two focuses on the technologies advancing peptide discovery and production. Experts in peptide discovery using AI and novel technologies, in chemical and biological peptide synthesis, flow chemistry and peptide formulation, will share strategies driving efficiency and scalability.

Discussions will explore how these disciplines converge to shape the future of peptide development.

Monday, 7th September 2026

- 8:45 **Welcoming**
Bernard Thorens
& PolyPeptide Group
- 9:00 **GLP-1:
the medicines, the biology,
and the learnings**
Lotte Bjerre Knudsen
- 9:45 **GLP-1 Analogues and their impact
on patients – the doctor's
perspective**
Katharina Timper
- 10:30 **Break**
- 11:00 **Discovery of novel unimolecular
tetra-agonist peptides for the
treatment of obesity and related
disorders**
Cristina M Rondinone
- 11:45 **From GLP-1 to Nutrient-Stimulated
Polyagonists: from T2D to Obesity
to Cardiorenalmetabolism and
Beyond**
Robert Augustin
- 12:30 **Lunch**
- 14:00 **Nano- and microtechnologies for
the oral delivery of peptides**
Patrick Couvreur
- 14:45 **Round Table**
Bernard Thorens
Metabolic space
What's next ?
- 18:00 **Cocktail hour**
- 19:00 **Networking dinner**

Tuesday, 8th September 2026

- The Infinite Loop: ML for Discovery,
Delivery, and Rapid Manufacturing
of Potential Medicines** 8:00
Bradley L. Pentelute
- Reprogramming the genetic code to
unlock the potential of recombinant
strategy for peptide manufacturing** 8:45
Jason Chin
- Break** 9:30
- Advances in AI Enabled Peptide
Design: Structural Trends and the
Expanding Role of AlphaFold** 10:00
Bruno Correia
- Diseconomies of Scale; how
Automation, Process Intensification
and Politics are changing
Manufacture of Complex Molecules** 10:45
Andrew Rutter
- Round Table** 11:30
Bernard Thorens
The promises of peptide science for
medicine
- Lunch** 12:30
- Closure** 13:30
30 min